Drug Profile
Pezadeftide - Hexima
Alternative Names: HXP-124Latest Information Update: 01 Mar 2022
Price :
$50
*
At a glance
- Originator Hexima
- Class Antifungals; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Onychomycosis
Most Recent Events
- 23 Feb 2022 Phase-II clinical trials in Onychomycosis in Australia (Topical) before February 2022 (Hexima pipeline, February 2022)
- 23 Jun 2020 Hexima plans a phase II trial for Onychomycosis in Australia in June 2020 (Topical) (ACTRN12620000697987)
- 05 Feb 2018 Pharmacokinetics, pharmacodynamics and adverse events data from preclinical studies in Onychomycosis released by Hexima